Table 2.
Univariate analysis for PFS in EOC patients with FIGO stage IV with isolated NLNMs metastasis
| Variables | Recurrence | No Recurrence | Log rank p-value | |
|---|---|---|---|---|
| Age | ≤ 60 | 14 | 6 | 0.132 |
| > 60 | 1 | 3 | ||
| CA125 | < 600U/ml | 6 | 4 | 0.711 |
| ≥ 600U/ml | 9 | 5 | ||
| Ascites | No | 6 | 2 | 0.112 |
| < 500 ml | 7 | 7 | ||
| ≥ 500 ml | 2 | 0 | ||
| RD | R0 | 5 | 8 | 0.001 |
| R1/R2 | 9 | 1 | ||
| Surgery | IDS | 12 | 9 | 0.427 |
| PDS | 2 | 0 | ||
| NLNM size | ≤ 2 cm | 11 | 6 | 0.908 |
| > 2 cm | 4 | 3 | ||
| BRAC gene testing | BRCA mutant | 3 | 2 | 0.693 |
| BRCA wild-type/BRCA status unknown | 12 | 7 | ||
| Sites of first recurrence | lymph nodes | 4 | - | 0.066 |
| Abdomen or other distant sites(lung,brain,bone,…) | 11 | - | ||
| Maintenance therapy | Not obtain PARPi maintenance therapy | 12 | 6 | 0.233 |
| Obtain PARPi maintenance therapy | 3 | 3 | ||